Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2015

01-02-2015 | Review Article

Prevalence and incidence of chronic kidney disease stage G5 in Japan

Authors: Kunihiro Yamagata, Takashi Yagisawa, Shigeru Nakai, Masaaki Nakayama, Enyu Imai, Motoshi Hattori, Kunitoshi Iseki, Takashi Akiba

Published in: Clinical and Experimental Nephrology | Issue 1/2015

Login to get access

Abstract

The prevalence and incidence of end-stage kidney disease (ESKD) have continued to increase worldwide. Japan was known as having the highest prevalence of ESKD in the world; however, Taiwan took this place in 2001, with the USA still in third position. However, the prevalence data from Japan and Taiwan consisted of dialysis patients only. The prevalence and incidence of Kidney Transplantation (KT) in Japan were quite low, and the number of KT patients among those with ESKD was regarded as negligibly small. However, the number of KT recipients has increased recently. Furthermore, there are no reports about nationwide surveys on the prevalence and incidence of predialysis chronic kidney failure patients in Japan. This review describes our recent study on the estimated number of chronic kidney disease (CKD) stage G5 patients and the number of ESKD patients living in Japan, obtained via the cooperation of five related medical societies. From the results, as of Dec 31, 2007, 275,242 patients had received dialysis therapy and 10,013 patients had a functional transplanted kidney, and as of Dec 31, 2008, 286,406 patients had received dialysis therapy and 11,157 patients had a functional transplanted kidney. Consequently, there were 285,255 patients with CKD who reached ESKD and were living in Japan in 2008 and 297,563 in 2009. We also estimated that there were 67,000 predialysis CKD stage G5 patients in 2009, 37,365 patients introduced to dialysis therapy, and 101 patients who received pre-emptive renal transplantation in this year. In total, there were 37,466 patients who newly required renal replacement therapy (RRT) in 2009. Not only the average ages, but also the primary renal diseases of the new ESKD patients in each RRT modality were different.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–59.CrossRefPubMed Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–59.CrossRefPubMed
2.
go back to reference Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16:483–521.CrossRefPubMed Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16:483–521.CrossRefPubMed
3.
go back to reference Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37–40.PubMed Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37–40.PubMed
4.
go back to reference System, USRD: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2009 USRDS Annual data report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009. System, USRD: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2009 USRDS Annual data report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
5.
go back to reference JSCRT, JST: Annual Progress report from the Japanese Renal Transplant Registry, 2010. Part III: results from 2009 Recipient Follow-up Survey. Transplantation 2010;45:608–630 (in Japanese). JSCRT, JST: Annual Progress report from the Japanese Renal Transplant Registry, 2010. Part III: results from 2009 Recipient Follow-up Survey. Transplantation 2010;45:608–630 (in Japanese).
6.
go back to reference Foley RN, Collins AJ. The USRDS: what you need to know about what it can and can’t tell us about ESRD. Clin J Am Soc Nephrol. 2013;8:845–51.CrossRefPubMed Foley RN, Collins AJ. The USRDS: what you need to know about what it can and can’t tell us about ESRD. Clin J Am Soc Nephrol. 2013;8:845–51.CrossRefPubMed
7.
go back to reference Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial. 2010;14:505–40.CrossRefPubMed Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial. 2010;14:505–40.CrossRefPubMed
8.
go back to reference Iseki K, Nakai S, Yamagata K, Tsubakihara Y. Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant. 2011;26:963–9.CrossRefPubMed Iseki K, Nakai S, Yamagata K, Tsubakihara Y. Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant. 2011;26:963–9.CrossRefPubMed
9.
go back to reference Yamagata K, Nakai S, Masakane I, Hanafusa N, Iseki K, Tsubakihara Y. Ideal timing and predialysis nephrology care duration for dialysis initiation: from analysis of Japanese dialysis initiation survey. Ther Apher Dial. 2012;16:54–62.CrossRefPubMed Yamagata K, Nakai S, Masakane I, Hanafusa N, Iseki K, Tsubakihara Y. Ideal timing and predialysis nephrology care duration for dialysis initiation: from analysis of Japanese dialysis initiation survey. Ther Apher Dial. 2012;16:54–62.CrossRefPubMed
10.
go back to reference Nakai S. History of JSDT renal data registry (in Japanese). J Jpn Soc Dial Ther. 2010;43:119–52.CrossRef Nakai S. History of JSDT renal data registry (in Japanese). J Jpn Soc Dial Ther. 2010;43:119–52.CrossRef
12.
go back to reference Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed
13.
go back to reference Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.CrossRefPubMed Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.CrossRefPubMed
14.
go back to reference Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, et al. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Hypertens Res. 2011;34:1106–10.CrossRefPubMed Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, et al. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Hypertens Res. 2011;34:1106–10.CrossRefPubMed
15.
go back to reference Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol. 2010;14:333–9.CrossRefPubMed Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol. 2010;14:333–9.CrossRefPubMed
16.
go back to reference Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial. 2012;16:11–53.CrossRefPubMed Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial. 2012;16:11–53.CrossRefPubMed
17.
go back to reference Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, et al. Chronic kidney disease Japan cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008;31:1101–7.CrossRefPubMed Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, et al. Chronic kidney disease Japan cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008;31:1101–7.CrossRefPubMed
18.
go back to reference Yamagata K, Makino H, Akizawa T, Iseki K, Itoh S, Kimura K, et al. Design and methods of a strategic outcome study for chronic kidney disease: frontier of renal outcome modifications in Japan. Clin Exp Nephrol. 2010;14:144–51.CrossRefPubMed Yamagata K, Makino H, Akizawa T, Iseki K, Itoh S, Kimura K, et al. Design and methods of a strategic outcome study for chronic kidney disease: frontier of renal outcome modifications in Japan. Clin Exp Nephrol. 2010;14:144–51.CrossRefPubMed
19.
go back to reference Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2009;13:457–504.CrossRefPubMed Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2009;13:457–504.CrossRefPubMed
20.
go back to reference Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial Off Peer Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2010;14:505–40. Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial Off Peer Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2010;14:505–40.
21.
go back to reference Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis. 1996;28:420–7.CrossRefPubMed Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis. 1996;28:420–7.CrossRefPubMed
Metadata
Title
Prevalence and incidence of chronic kidney disease stage G5 in Japan
Authors
Kunihiro Yamagata
Takashi Yagisawa
Shigeru Nakai
Masaaki Nakayama
Enyu Imai
Motoshi Hattori
Kunitoshi Iseki
Takashi Akiba
Publication date
01-02-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0978-x

Other articles of this Issue 1/2015

Clinical and Experimental Nephrology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.